Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 11/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 8/20 | 0.37 |
| ▸ | PPARD | Q03181 | 3/20 | 0.37 |
| ▸ | FABP4 | P15090 | 2/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7523575 | 0.95 | PPARD (0.38) | S1PR5S1PR4PPARDFABP4PTPN1 | |
| SCHEMBL7521979 | 0.88 | ALDH1A1 (0.40) | PTPN1MAPTTP53POLBKDM4E | |
| SCHEMBL7527054 | 0.87 | PPARD (0.38) | PPARDPTPN1MAPTTP53POLB | |
| SCHEMBL7523863 | 0.87 | TP53 (0.44) | PPARDMAPTTP53POLBKDM4E | |
| SCHEMBL7527946 | 0.78 | PPARD (0.39) | S1PR5S1PR4PPARDFABP4PTPN1 | |
| SCHEMBL7523182 | 0.70 | PTGDR2 (0.41) | PPARD | |
| SCHEMBL7520993 | 0.70 | PTGDR2 (0.43) | PPARDPTPN1 | |
| SCHEMBL7524434 | 0.69 | TP53 (0.41) | PPARDMAPTTP53POLBKDM4E | |
| SCHEMBL7518610 | 0.69 | PTGIR (0.41) | PPARDKDM4ELMNA | |
| SCHEMBL7523911 | 0.69 | PTGIR (0.39) | PPARDMAPTTP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6417213-B2 | ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-07-09 | — | — | US | disclosed |
| US-20020006944-A1 | Tricyclic compounds, their production and use | OHKAWA SHIGENORI (JP) | 2002-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006944-A1 | Tricyclic compounds, their production and use | CNR1, PTGER1, PTGDR | S1PR5 358/4885S1PR4 405/4885PPARD 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.